Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is an artificial-intelligence-driven cardiovascular diagnostics company that completed its de-SPAC merger with Mana Capital Acquisition Corp, sponsored by Mana Capital LLC, and began trading as a combined public entity in 2022. The company operates in the healthcare and molecular diagnostics sector, applying epigenetic biomarker technology to cardiovascular disease risk assessment. Cardio Diagnostics filed a Form 10-Q with the SEC on May 12, 2022, reflecting its status as a newly public reporting company following the business combination. The filing covers operational and financial disclosures for the period immediately after the merger close. Visit SpacDesk and sign up for full data, filings history, and analytics on CDIO and hundreds of other SPAC transactions.